Argent Biopharma (AU:RGT)
ASX:RGT
Top Page
Argent Biopharma
(Sydney:RGT)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.04
â–Ľ(-48.75% Downside)
Action:UpgradedDate:03/24/26
The score is driven primarily by very weak financial performance (steep revenue decline, large losses, negative equity, and heavy free-cash-flow burn), reinforced by bearish technicals (price below key moving averages with negative MACD). Valuation metrics provide limited support because P/E is not meaningful and there is no dividend yield data.
Positive Factors
Improved Gross Margin
A material gross margin improvement in 2025 indicates stronger unit economics or a higher-margin product mix. If sustained, higher gross margins provide a structural lever to restore profitability once fixed operating costs are controlled or revenue stabilizes, improving long-term earnings power.
Negative Factors
Negative Equity
Sustained negative equity is a deep structural weakness that limits financial flexibility, raises insolvency risk, and hampers ability to raise non-dilutive capital. It constrains strategic options, increases creditor scrutiny, and makes long-term R&D or commercialization investments harder without decisive balance-sheet repair.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Gross Margin
A material gross margin improvement in 2025 indicates stronger unit economics or a higher-margin product mix. If sustained, higher gross margins provide a structural lever to restore profitability once fixed operating costs are controlled or revenue stabilizes, improving long-term earnings power.
Read all positive factors
Argent Biopharma (RGT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$3.39M
Dividend YieldN/A
Average Volume (3M)77.74K
Price to Earnings (P/E)―
Beta (1Y)-0.77
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.04
Shares Outstanding89,192,314
10 Day Avg. Volume131,422
30 Day Avg. Volume77,736
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Argent Biopharma Business Overview & Revenue Model
Company Description
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal p...
How the Company Makes Money
null...
Argent Biopharma Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
9
Very Negative
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 583.45K | 891.08K | 3.39M | 4.73M |
| Gross Profit | 446.32K | 203.70K | 1.45M | 1.81M |
| EBITDA | -17.00M | -15.77M | -20.04M | -16.70M |
| Net Income | -17.84M | -17.53M | -20.82M | -16.77M |
Balance Sheet | ||||
| Total Assets | 2.47M | 10.79M | 9.88M | 23.55M |
| Cash, Cash Equivalents and Short-Term Investments | 1.02M | 702.87K | 239.82K | 1.79M |
| Total Debt | 8.29M | 1.04M | 575.14K | 4.39M |
| Total Liabilities | 11.10M | 16.61M | 18.02M | 13.66M |
| Stockholders Equity | -8.63M | -5.15M | -7.51M | 11.23M |
Cash Flow | ||||
| Free Cash Flow | -9.28M | -14.40M | -11.26M | -14.85M |
| Operating Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 |
| Investing Cash Flow | 208.83K | -140.12K | 51.75K | -2.44M |
| Financing Cash Flow | 9.39M | 14.87M | 9.31M | 9.74M |
Argent Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$25.18M | -12.06 | 1.66% | 3.28% | 0.13% | -12.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$2.90M | -0.42 | -76.30% | ― | 36.60% | 85.28% | |
43 Neutral | AU$3.39M | ― | 258.94% | ― | ― | ― | |
43 Neutral | AU$19.73M | -2.87 | 4388.00% | ― | -47.30% | 82.53% | |
39 Underperform | AU$9.58M | 0.07 | 93.89% | ― | -26.49% | 61.72% |
* Healthcare Sector Average
AU:RGT
Argent Biopharma
0.04
-0.14
-78.89%
AU:EXL
Elixinol Wellness
0.01
-0.02
-66.67%
AU:CAN
Cann Group
0.01
-0.01
-52.38%
AU:LGP
Little Green Pharma Ltd.
0.10
-0.02
-19.17%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-19.05%
AU:VIT
Cronos Australia Ltd.
0.04
-0.03
-39.68%
Argent Biopharma Corporate Events
Argent BioPharma Clears Secondary Trading for New Share Issue
Mar 20, 2026
Argent BioPharma has notified investors of the issue of 1,250,000 fully paid ordinary shares, confirming that the securities were issued without a disclosure document under Australian law but qualify for on-sale under the relevant exemption. The c...
Argent Biopharma Seeks ASX Quotation for 1.25 Million New Shares
Mar 20, 2026
Argent Biopharma Limited has applied for quotation on the ASX of 1,250,000 new fully paid ordinary shares under the code RGT, with an issue date of March 20, 2026. The additional securities broaden the company’s free float and may enhance tr...
Argent Biopharma Issues 2.5 Million Unquoted Performance Rights Under Incentive Scheme
Mar 20, 2026
Argent Biopharma Limited has notified the market of the issue of 2,500,000 unquoted performance rights under its employee incentive scheme. The new securities, which will not be quoted on the ASX, were issued on March 20, 2026, and are intended to...
Argent Biopharma Issues 2.1 Million New Unquoted Options
Mar 20, 2026
Argent Biopharma has notified the market of the issue of 2,100,000 unquoted options, exercisable at A$0.20 and expiring on 20 March 2029. The new options, to be listed under a new security class on the ASX, signal the company’s continued use...
Argent BioPharma Sets April General Meeting for Shareholders
Mar 6, 2026
Argent BioPharma has dispatched documentation for a General Meeting of shareholders scheduled for 10:00 a.m. AWST on 8 April 2026 in Subiaco, Western Australia. Shareholders are encouraged to participate either in person or by lodging proxies onli...
Argent BioPharma Clears 1 Million New Shares for On-Sale Under Disclosure Exemption
Feb 27, 2026
Argent BioPharma has issued 1,000,000 fully paid ordinary shares and confirmed that these securities can be freely traded under the exemption provisions of section 708A(5) of the Corporations Act 2001. The company stated that the shares were issue...
Argent Biopharma Seeks ASX Quotation for 1 Million New Shares
Feb 27, 2026
Argent Biopharma Limited has applied for quotation of 1,000,000 ordinary fully paid shares on the Australian Securities Exchange under the code RGT. The newly quoted securities, issued on February 27, 2026, modestly expand the company’s list...
Argent Biopharma Narrows Half-Year Loss as Revenue Jumps but Going Concern Risks Flagged
Feb 27, 2026
Argent Biopharma reported interim revenue of $171,499 for the half year to 31 December 2025, a sharp rise from $4,283 a year earlier, while cutting its net loss attributable to members to $2.94 million from $12.16 million. The company did not decl...
Argent BioPharma Files U.S. Provisional Patent for NanoBodies Platform Targeting Septic Shock
Feb 25, 2026
Argent BioPharma has filed a U.S. provisional patent application for its NanoBodies platform, securing priority protection for proprietary peptide targets and nanobody constructs aimed at vascular and peptide-mediated signalling in septic shock an...
Argent BioPharma Clears Compliance Path for New Share Issue
Feb 10, 2026
Argent BioPharma has issued 2,557,450 fully paid ordinary shares and confirmed that these were made without a prospectus under the disclosure exemptions of Australia’s Corporations Act. The company stated it remains compliant with its financ...
Argent Biopharma Seeks ASX Quotation for Over 2.5 Million New Shares
Feb 10, 2026
Argent Biopharma Limited has applied to the ASX for quotation of 2,557,450 new ordinary fully paid shares. The securities are being issued as consideration for purchase order reimbursement, reflecting a non-cash settlement structure with counterpa...
Argent BioPharma Clears 1 Million New Shares for On‑Sale Under Corporations Act Exemption
Jan 15, 2026
Argent BioPharma has issued 1,000,000 fully paid ordinary shares and notified the market that these securities qualify for on‑sale without a prospectus under section 708A(5) of the Corporations Act. The company affirmed it is compliant with ...
Argent Biopharma Seeks Quotation of 1 Million New Shares on ASX
Jan 15, 2026
Argent Biopharma Limited, listed on the ASX under the code RGT, has applied for quotation of an additional 1,000,000 ordinary fully paid shares. The new securities, issued on 15 January 2026 following the exercise or conversion of existing options...
Argent Biopharma Plans Placement of Up to 20 Million New Shares
Jan 13, 2026
Argent Biopharma Limited has notified the ASX of its intention to issue up to 20 million new fully paid ordinary shares in a proposed placement, with an expected issue date of 16 March 2026. The additional securities, to be quoted on the ASX subje...
Argent BioPharma Streamlines AusCann Deal to Bolster CannEpil and IP Portfolio
Jan 13, 2026
Argent BioPharma has signed a binding agreement with AusCann Group Holdings to acquire AusCann’s 48% equity stake in CannPal Animal Therapeutics for A$2 million in Argent shares, in a streamlined deal that replaces a broader prior term sheet...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.